FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:C19orf33-SYNPO2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: C19orf33-SYNPO2
FusionPDB ID: 11193
FusionGDB2.0 ID: 11193
HgeneTgene
Gene symbol

C19orf33

SYNPO2

Gene ID

64073

171024

Gene namechromosome 19 open reading frame 33synaptopodin 2
SynonymsH2RSP|IMUP|IMUP-1|IMUP-2-
Cytomap

19q13.2

4q26

Type of geneprotein-codingprotein-coding
Descriptionimmortalization up-regulated proteinHAI-2 related small proteinhepatocyte growth factor activator inhibitor type 2-related small proteinimmortalization-upregulated proteinsynaptopodin-2genethonin-2myopodin
Modification date2020031320200313
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000588605, ENST00000301246, 
ENST00000307142, ENST00000429713, 
ENST00000434046, ENST00000448416, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score1 X 1 X 1=111 X 11 X 4=484
# samples 112
** MAII scorelog2(1/1*10)=3.32192809488736log2(12/484*10)=-2.01197264166608
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: C19orf33 [Title/Abstract] AND SYNPO2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: C19orf33 [Title/Abstract] AND SYNPO2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)C19orf33(38795326)-SYNPO2(119944584), # samples:1
Anticipated loss of major functional domain due to fusion event.C19orf33-SYNPO2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
C19orf33-SYNPO2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
C19orf33-SYNPO2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
C19orf33-SYNPO2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:38795326/chr4:119944584)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across C19orf33 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across SYNPO2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000301246C19orf33chr1938795326+ENST00000307142SYNPO2chr4119944584+729630210139821293
ENST00000301246C19orf33chr1938795326+ENST00000448416SYNPO2chr4119944584+1346302101568155
ENST00000301246C19orf33chr1938795326+ENST00000429713SYNPO2chr4119944584+725730210134781125
ENST00000301246C19orf33chr1938795326+ENST00000434046SYNPO2chr4119944584+372130210135261141

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000301246ENST00000307142C19orf33chr1938795326+SYNPO2chr4119944584+0.000136050.999864
ENST00000301246ENST00000448416C19orf33chr1938795326+SYNPO2chr4119944584+0.0071071770.99289286
ENST00000301246ENST00000429713C19orf33chr1938795326+SYNPO2chr4119944584+0.0002142550.9997857
ENST00000301246ENST00000434046C19orf33chr1938795326+SYNPO2chr4119944584+0.0011890470.998811

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for C19orf33-SYNPO2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
C19orf33chr1938795326SYNPO2chr411994458430267SSSSSSDSDTDVKIRNQSKASGSGLC

Top

Potential FusionNeoAntigen Information of C19orf33-SYNPO2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
C19orf33-SYNPO2_38795326_119944584.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
C19orf33-SYNPO2chr1938795326chr4119944584302HLA-C05:09SSDSDTDVKI0.99980.6369414
C19orf33-SYNPO2chr1938795326chr4119944584302HLA-C05:01SSDSDTDVKI0.99980.6369414

Top

Potential FusionNeoAntigen Information of C19orf33-SYNPO2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
C19orf33-SYNPO2_38795326_119944584.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0804TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0804DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0804DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0820TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0820DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0820DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0824TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0824DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0828TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0828DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0828DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0831TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0831DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0831DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-0831VKIRNQSKASGSGLC1126
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1103TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1103DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1103DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1104TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1104DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1104DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1106DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1106TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1106DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1106VKIRNQSKASGSGLC1126
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1118DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1118TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1125TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1125DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1125DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1134DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1134TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1135TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1135DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1135DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1136TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1136DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1137TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1137DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1138TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1138DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1138DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1141TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1141DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1141DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1142TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1142DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1142DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1143TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1143DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1143DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1144TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1144DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1144DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1146TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1146DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1146DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1147DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1147TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1147DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1147VKIRNQSKASGSGLC1126
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1148TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1148DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1150TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1150DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1150DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1150VKIRNQSKASGSGLC1126
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1154TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1154DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1155TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1155DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1155DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1156TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1156DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1156DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1156VKIRNQSKASGSGLC1126
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1157DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1157TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1158TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1158DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1158DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1159TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1159DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1159DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1160TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1160DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1160DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1163TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1163DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1163DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1167TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1167DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1167DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1169TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1169DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1176TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1176DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1176DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1177TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1177DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1177DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1178TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1178DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1178DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1180TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1180DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1183TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1183DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1183DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1183VKIRNQSKASGSGLC1126
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1184DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1184TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1184DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1185TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1185DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1185DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1187TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1187DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1188TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1188DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1188DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1188VKIRNQSKASGSGLC1126
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1192TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1192DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1193TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1193DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1306DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1306TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1307TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1307DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1308TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1308DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1309TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1309DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1309DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1311TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1311DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1311DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1318TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1318DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1318DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1320TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1320DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1324TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1324DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1324DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1326TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1326DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1327TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1327DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1342TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1342DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1342DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1344DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1344TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1370TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1370DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1371TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1371DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1372TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1372DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1375TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1378TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1378DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1384TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1384DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1402DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1402TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1406DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1406TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1406DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1409TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1409DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1412TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1412DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1412DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1415TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1415DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1415DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1417DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1417TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1420DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1420TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1420DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1421DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1421TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1421DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1429DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1429TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1429DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1433TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1434TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1434DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1437TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1437DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1437DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1441DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1441TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1452TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1452DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1452DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1480TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1480DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1480DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1481TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1481DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1483DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1483TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1483DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1484TDVKIRNQSKASGSG924
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1484DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1484DTDVKIRNQSKASGS823
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1494DVKIRNQSKASGSGL1025
C19orf33-SYNPO2chr1938795326chr4119944584302DRB1-1494TDVKIRNQSKASGSG924

Top

Fusion breakpoint peptide structures of C19orf33-SYNPO2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
1396DSDTDVKIRNQSKAC19orf33SYNPO2chr1938795326chr4119944584302

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of C19orf33-SYNPO2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN1396DSDTDVKIRNQSKA-5.09731-5.09731
HLA-A11:014UQ21396DSDTDVKIRNQSKA-6.94957-6.94957
HLA-A24:025HGA1396DSDTDVKIRNQSKA-7.40535-7.40535

Top

Vaccine Design for the FusionNeoAntigens of C19orf33-SYNPO2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
C19orf33-SYNPO2chr1938795326chr4119944584414SSDSDTDVKITCCAGCGATTCGGACACGGATGTGAAGATT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
C19orf33-SYNPO2chr1938795326chr41199445841025DVKIRNQSKASGSGLGATGTGAAGATTCGAAATCAGAGCAAAGCCTCTGGGTCTGGGCTC
C19orf33-SYNPO2chr1938795326chr41199445841126VKIRNQSKASGSGLCGTGAAGATTCGAAATCAGAGCAAAGCCTCTGGGTCTGGGCTCTGT
C19orf33-SYNPO2chr1938795326chr4119944584823DTDVKIRNQSKASGSGACACGGATGTGAAGATTCGAAATCAGAGCAAAGCCTCTGGGTCT
C19orf33-SYNPO2chr1938795326chr4119944584924TDVKIRNQSKASGSGACGGATGTGAAGATTCGAAATCAGAGCAAAGCCTCTGGGTCTGGG

Top

Information of the samples that have these potential fusion neoantigens of C19orf33-SYNPO2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADC19orf33-SYNPO2chr1938795326ENST00000301246chr4119944584ENST00000307142TCGA-BR-4292

Top

Potential target of CAR-T therapy development for C19orf33-SYNPO2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to C19orf33-SYNPO2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to C19orf33-SYNPO2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource